CODA Biotherapeutics acquires Attenua and three clinical stage assets

CODA Biotherapeutics, a biopharmaceutical company developing a gene therapy approach for the treatment of neurological diseases, announced the acquisition of Attenua with its three clinical stage small molecule drugs. CODA has engineered a set of ligand-gated ion channels that can be specifically controlled by these drugs.

CODA plans to advance these unique channel-ligand pairs toward the clinic to treat neuropathic pain, focal epilepsy, and other neurologic diseases and disorders.

Read more about CODA Biotherapeutics here.

Image by Gerd Altmann from Pixabay